{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:50:53Z","timestamp":1792900253784,"version":"4.5.0"},"reference-count":30,"publisher":"Scientific Scholar","issue":"01","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":2825,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurosciences in Rural Practice"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Heroin dependence is a major health and social problem associated with increased morbidity and mortality that adversely affects social circumstances, productivity, and healthcare and law enforcement costs. In the UK and many other Western countries, both methadone and buprenorphine are recommended by the relevant agencies for detoxification from heroin and for opioid maintenance therapy. However, despite obvious benefits due to its unique pharmacotherapy (eg, greatly reduced risk of overdose), buprenorphine has largely failed to overtake methadone in managing opioid addiction. The experience from the developing world (based on data from India) is similar. In this article we compare the advantages and disadvantages of the use methadone and buprenorphine for the treatment of opioid addiction from both a developed and developing world perspective; and explore some of the reasons why buprenorphine has not fulfilled the expectations predicted by many in the addictions field.<\/jats:p>","DOI":"10.4103\/0976-3147.91934","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T09:46:14Z","timestamp":1326793574000},"page":"45-50","source":"Crossref","is-referenced-by-count":169,"title":["Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds"],"prefix":"10.25259","volume":"03","author":[{"given":"Paul J","family":"Whelan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central and North West London NHS Foundation Trust, North Westminster Community Mental Health Team for Older Adults, Latimer House, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Remski","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central and North West London NHS Foundation Trust, North Westminster Community Mental Health Team for Older Adults, Latimer House, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"key":"key-10.4103\/0976-3147.91934-1","unstructured":"Health Protection Agency. Shooting up: Infections among injecting drug users in the United Kingdom 2005. London: Health Protection Agency 2006."},{"key":"key-10.4103\/0976-3147.91934-2","first-page":"425","volume-title":"Deaths of drug addicts in the United Kingdom 1967-81","author":"Ghodse","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"key-10.4103\/0976-3147.91934-3","first-page":"331","volume-title":"Heroin use and acquisitive crime in an English community","author":"Parker","year":"1987","journal-title":"Br J Sociol"},{"key":"key-10.4103\/0976-3147.91934-4","unstructured":"World Health Organization, Department of mental health and substance misuse. Proposal for the inclusion of buprenorphine in the WHO model list of essential medicines. WHO 2004. Available from: http:\/\/www.who.int\/substance_abuse\/activities\/buprenorphine_essential_medicines.pdf. [Last accessed: 2011]."},{"key":"key-10.4103\/0976-3147.91934-5","unstructured":"United Nations Drug Control Programme. Available from: http:\/\/www.un.org\/Docs\/SG\/SG-Rpt\/ch3c-5.htm. [Last accessed on 2000]."},{"key":"key-10.4103\/0976-3147.91934-6","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2009;152-6."},{"key":"key-10.4103\/0976-3147.91934-7","unstructured":"Clinical practice guidelines for management of opioid dependence. Indian Psychiatr Soc 2004."},{"key":"key-10.4103\/0976-3147.91934-8","first-page":"104","volume-title":"Mortality associated with New South Wales methadone programs in 1994: lives lost and saved","author":"Caplehorn","year":"1999","journal-title":"Med J Aust"},{"key":"key-10.4103\/0976-3147.91934-9","first-page":"457","volume-title":"Characterization of methadone overdose: clinical considerations and the scientific evidence","author":"Wolff","year":"2002","journal-title":"Ther Drug Monit"},{"key":"key-10.4103\/0976-3147.91934-10","first-page":"277","volume-title":"An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence","author":"Rothman","year":"2000","journal-title":"J Subst Abuse Treat"},{"key":"key-10.4103\/0976-3147.91934-11","first-page":"CD002207","volume-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0976-3147.91934-12","doi-asserted-by":"crossref","unstructured":"Ray R, Pal H, Kumar R, Maulick P, Mangla R. Post-marketing surveillance of buprenorphine. Pharmacoepidemiol Drug Saf 2004;13;615-9.","DOI":"10.1002\/pds.975"},{"key":"key-10.4103\/0976-3147.91934-13","first-page":"53","volume-title":"Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects","author":"De","year":"2008","journal-title":"Indian J Physiol Pharmacol"},{"key":"key-10.4103\/0976-3147.91934-14","first-page":"CD002025","volume-title":"Buprenorphine for the management of opioid withdrawal","author":"Gowing","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0976-3147.91934-15","first-page":"1","volume-title":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation","author":"Connock","year":"2007","journal-title":"Health Technol Assess"},{"key":"key-10.4103\/0976-3147.91934-16","doi-asserted-by":"crossref","unstructured":"Wolff K, editor. Substance Misuse: Substitution drugs (methadone and buprenorphine) Oxford: Elsevier; 2005.","DOI":"10.1016\/B0-12-369399-3\/00350-5"},{"key":"key-10.4103\/0976-3147.91934-17","first-page":"79","volume-title":"Does high-dose buprenorphine cause respiratory depression.: possible mechanisms and therapeutic consequences?","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Rev"},{"key":"key-10.4103\/0976-3147.91934-18","first-page":"959","volume-title":"Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992","author":"Hammersley","year":"1995","journal-title":"Addiction"},{"key":"key-10.4103\/0976-3147.91934-19","first-page":"S17","volume-title":"French field experience with buprenorphine","author":"Auriacombe","year":"2004","journal-title":"Am J Addict"},{"key":"key-10.4103\/0976-3147.91934-20","first-page":"197","volume-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"key-10.4103\/0976-3147.91934-21","first-page":"107","volume-title":"Abuse of buprenorphine in the United States: 2003-2005","author":"Smith","year":"2007","journal-title":"J Addict Dis"},{"key":"key-10.4103\/0976-3147.91934-22","first-page":"450","volume-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia","author":"Winstock","year":"2008","journal-title":"Int J Drug Policy"},{"key":"key-10.4103\/0976-3147.91934-23","unstructured":"Cowan A, Lewis JW, editors. Buprenorphine: combating drug abuse with a unique opioid. Chichester: Wiley-Liss; 1995."},{"key":"key-10.4103\/0976-3147.91934-24","unstructured":"Department of Health. Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health; 2007."},{"key":"key-10.4103\/0976-3147.91934-25","first-page":"79","volume-title":"Physician awareness of the cardiac effects of methadone: results of a national survey","author":"Krantz","year":"2007","journal-title":"J Addict Dis"},{"key":"key-10.4103\/0976-3147.91934-26","unstructured":"Ganguly K. The pattern and process of drug and alcohol use in India. ICMR Bull 2008; Available from: http:\/\/www.icmr.nic.in\/bulletin\/english\/2008\/bulljan-mar08.pdf. [Last accessed on 2008]."},{"key":"key-10.4103\/0976-3147.91934-27","doi-asserted-by":"crossref","unstructured":"Taylor D, Paton C, Kerwin R. The Maudsley prescribing Guidelines 9 th ed. London: Informa Healthcare; 2007.","DOI":"10.1201\/b21605"},{"key":"key-10.4103\/0976-3147.91934-28","first-page":"275","volume-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study","author":"Fischer","year":"2006","journal-title":"Addiction"},{"key":"key-10.4103\/0976-3147.91934-29","doi-asserted-by":"crossref","unstructured":"Ball J, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services and outcome. New York: Springer-Verlag; 1991.","DOI":"10.1007\/978-1-4613-9089-3"},{"key":"key-10.4103\/0976-3147.91934-30","unstructured":"National Institute of Health and Clinical Excellence. Drug misuse: psychosocial interventions: NICE guideline 51. Available from: http:\/\/guidance.nice.org.uk\/CG51. [Last accessed in 2011]."}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/0976-3147.91934.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T04:24:29Z","timestamp":1691209469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/buprenorphine-vs-methadone-treatment-a-review-of-evidence-in-both-developed-and-developing-worlds\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":30,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2019,9,26]]},"published-print":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.4103\/0976-3147.91934","relation":{},"ISSN":["0976-3147","0976-3155"],"issn-type":[{"value":"0976-3147","type":"print"},{"value":"0976-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}